Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells.

Li DD, Yagüe E, Wang LY, Dai LL, Yang ZB, Zhi S, Zhang N, Zhao XM, Hu YH.

ACS Med Chem Lett. 2019 Jul 25;10(9):1328-1335. doi: 10.1021/acsmedchemlett.9b00284. eCollection 2019 Sep 12.

PMID:
31531205
2.

EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer.

Mahmud Z, Gomes AR, Lee HJ, Aimjongjun S, Jiramongkol Y, Yao S, Zona S, Alasiri G, Gong G, Yagüe E, Lam EW.

Cancers (Basel). 2019 Jul 28;11(8). pii: E1067. doi: 10.3390/cancers11081067.

3.

Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells.

Ruenraroengsak P, Kiryushko D, Theodorou IG, Klosowski MM, Taylor ER, Niriella T, Palmieri C, Yagüe E, Ryan MP, Coombes RC, Xie F, Porter AE.

Nanoscale. 2019 Jul 11;11(27):12858-12870. doi: 10.1039/c9nr01277j.

PMID:
31157349
4.

Progression-Related Loss of Stromal Caveolin 1 Levels Mediates Radiation Resistance in Prostate Carcinoma via the Apoptosis Inhibitor TRIAP1.

Ketteler J, Panic A, Reis H, Wittka A, Maier P, Herskind C, Yagüe E, Jendrossek V, Klein D.

J Clin Med. 2019 Mar 12;8(3). pii: E348. doi: 10.3390/jcm8030348.

5.

Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.

Mahmud Z, Asaduzzaman M, Kumar U, Masrour N, Jugov R, Coombes RC, Shousha S, Hu Y, Lam EW, Yagüe E.

Biochem Pharmacol. 2019 May;163:391-403. doi: 10.1016/j.bcp.2019.03.009. Epub 2019 Mar 9.

PMID:
30862505
6.

Towards multiplexed near-infrared cellular imaging using gold nanostar arrays with tunable fluorescence enhancement.

Theodorou IG, Ruenraroengsak P, Gonzalez-Carter DA, Jiang Q, Yagüe E, Aboagye EO, Coombes RC, Porter AE, Ryan MP, Xie F.

Nanoscale. 2019 Jan 23;11(4):2079-2088. doi: 10.1039/c8nr09409h.

PMID:
30648720
7.

GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.

Liu J, Liu L, Yagüe E, Yang Q, Pan T, Zhao H, Hu Y, Zhang J.

Breast Cancer Res Treat. 2019 Feb;174(1):65-78. doi: 10.1007/s10549-018-5052-z. Epub 2018 Nov 19.

PMID:
30450530
8.

Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.

Hu Y, Yagüe E, Zhao J, Wang L, Bai J, Yang Q, Pan T, Zhao H, Liu J, Zhang J.

Cancer Lett. 2018 Jun 1;423:47-59. doi: 10.1016/j.canlet.2018.02.036. Epub 2018 Feb 27.

9.

Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Charles Coombes R, Lam EW, Hu Y, Yagüe E.

Breast Cancer Res Treat. 2018 Jan;167(2):605-606. doi: 10.1007/s10549-017-4633-6.

10.

Ruanjian Sanjie decoction exhibits antitumor activity by inducing cell apoptosis in breast cancer.

Zhao X, Zhao J, Hu R, Yao Q, Zhang G, Shen H, Yagüe E, Hu Y.

Oncol Lett. 2017 May;13(5):3071-3079. doi: 10.3892/ol.2017.5832. Epub 2017 Mar 8.

11.

Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Coombes RC, Lam EW, Hu Y, Yagüe E.

Breast Cancer Res Treat. 2017 Jun;163(3):461-474. doi: 10.1007/s10549-017-4202-z. Epub 2017 Mar 24. Erratum in: Breast Cancer Res Treat. 2018 Jan 5;:.

12.

miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.

Hu Y, Qiu Y, Yagüe E, Ji W, Liu J, Zhang J.

Cell Death Dis. 2016 Jun 30;7(6):e2291. doi: 10.1038/cddis.2016.194.

13.

MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.

Hu Y, Li K, Asaduzzaman M, Cuella R, Shi H, Raguz S, Coombes RC, Zhou Y, Yagüe E.

Oncol Rep. 2016 Feb;35(2):1170-8. doi: 10.3892/or.2015.4412. Epub 2015 Nov 12.

14.

Structural insight into the TRIAP1/PRELI-like domain family of mitochondrial phospholipid transfer complexes.

Miliara X, Garnett JA, Tatsuta T, Abid Ali F, Baldie H, Pérez-Dorado I, Simpson P, Yague E, Langer T, Matthews S.

EMBO Rep. 2015 Jul;16(7):824-35. doi: 10.15252/embr.201540229. Epub 2015 Jun 12.

15.

Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance.

Adams C, Cazzanelli G, Rasul S, Hitchinson B, Hu Y, Coombes RC, Raguz S, Yagüe E.

Oncol Rep. 2015 Jul;34(1):415-22. doi: 10.3892/or.2015.3988. Epub 2015 May 19.

16.

miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.

Hu Y, Xu K, Yagüe E.

Breast Cancer Res Treat. 2015 Jun;151(2):269-80. doi: 10.1007/s10549-015-3372-9. Epub 2015 Apr 22.

17.

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.

Alshaker H, Krell J, Frampton AE, Waxman J, Blyuss O, Zaikin A, Winkler M, Stebbing J, Yagüe E, Pchejetski D.

Breast Cancer Res. 2014 Oct 25;16(5):426. doi: 10.1186/s13058-014-0426-6.

18.

Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.

Alshaker H, Wang Q, Frampton AE, Krell J, Waxman J, Winkler M, Stebbing J, Cooper C, Yagüe E, Pchejetski D.

Breast Cancer Res Treat. 2015 Jan;149(1):59-67. doi: 10.1007/s10549-014-3228-8. Epub 2014 Dec 7.

PMID:
25481644
19.

Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.

Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y, Zhang Y, Yagüe E, Xiong D.

Breast Cancer Res Treat. 2014 Jan;143(2):287-99. doi: 10.1007/s10549-013-2809-2. Epub 2013 Dec 15.

20.

The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300.

Zhou Y, Hu Y, Yang M, Jat P, Li K, Lombardo Y, Xiong D, Coombes RC, Raguz S, Yagüe E.

Cell Death Differ. 2014 Mar;21(3):462-74. doi: 10.1038/cdd.2013.167. Epub 2013 Nov 22.

21.

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.

Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yagüe E, Monteiro LJ, Kongsema M, Zona S, Man EP, Tsang JW, Coombes RC, Wu KJ, Khoo US, Medema RH, Freire R, Lam EW.

Oncogene. 2014 Aug 7;33(32):4144-55. doi: 10.1038/onc.2013.457. Epub 2013 Oct 21.

22.

SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.

Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong S, Koo CY, Harada-Shoji N, Tsang JW, Coombes RC, Schwer B, Khoo US, Lam EW.

Carcinogenesis. 2013 Jul;34(7):1476-86. doi: 10.1093/carcin/bgt098. Epub 2013 Mar 20.

PMID:
23514751
23.

Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.

Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y, Cazzanelli G, Zhou Y, Patel N, Coombes C, Yagüe E.

Biochem Pharmacol. 2013 Jan 15;85(2):186-96. doi: 10.1016/j.bcp.2012.10.020. Epub 2012 Oct 30.

24.

Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo.

Lombardo Y, Filipović A, Molyneux G, Periyasamy M, Giamas G, Hu Y, Trivedi PS, Wang J, Yagüe E, Michel L, Coombes RC.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16558-63. doi: 10.1073/pnas.1206268109. Epub 2012 Sep 24.

25.

Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients.

Payne RE, Wang F, Su N, Krell J, Zebrowski A, Yagüe E, Ma XJ, Luo Y, Coombes RC.

Br J Cancer. 2012 May 22;106(11):1790-7. doi: 10.1038/bjc.2012.137. Epub 2012 Apr 26.

26.

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy.

Payne RE, Hava NL, Page K, Blighe K, Ward B, Slade M, Brown J, Guttery DS, Zaidi SA, Stebbing J, Jacob J, Yagüe E, Shaw JA, Coombes RC.

Br J Cancer. 2012 Jan 17;106(2):375-82. doi: 10.1038/bjc.2011.537. Epub 2011 Dec 13.

27.

Escape from stress granule sequestration: another way to drug resistance?

Yagüe E, Raguz S.

Biochem Soc Trans. 2010 Dec;38(6):1537-42. doi: 10.1042/BST0381537.

28.

mRNA escape from stress granule sequestration is dictated by localization to the endoplasmic reticulum.

Unsworth H, Raguz S, Edwards HJ, Higgins CF, Yagüe E.

FASEB J. 2010 Sep;24(9):3370-80. doi: 10.1096/fj.09-151142. Epub 2010 May 7.

29.

Biological and clinical implications of nicastrin expression in invasive breast cancer.

Filipović A, Gronau JH, Green AR, Wang J, Vallath S, Shao D, Rasul S, Ellis IO, Yagüe E, Sturge J, Coombes RC.

Breast Cancer Res Treat. 2011 Jan;125(1):43-53. doi: 10.1007/s10549-010-0823-1. Epub 2010 Mar 12.

PMID:
20224929
30.

Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.

Rasul S, Balasubramanian R, Filipović A, Slade MJ, Yagüe E, Coombes RC.

Br J Cancer. 2009 Jun 16;100(12):1879-88. doi: 10.1038/sj.bjc.6605034.

31.

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients.

Payne RE, Yagüe E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B, Coombes RC, Stebbing J.

Pharmacogenomics. 2009 Jan;10(1):51-7. doi: 10.2217/14622416.10.1.51.

PMID:
19102715
32.

Resistance to chemotherapy: new treatments and novel insights into an old problem.

Raguz S, Yagüe E.

Br J Cancer. 2008 Aug 5;99(3):387-91. doi: 10.1038/sj.bjc.6604510. Review.

33.

Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.

Raguz S, Randle RA, Sharpe ER, Foekens JA, Sieuwerts AM, Meijer-van Gelder ME, Melo JV, Higgins CF, Yagüe E.

Int J Cancer. 2008 Mar 1;122(5):1058-67.

34.

Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression.

Randle RA, Raguz S, Higgins CF, Yagüe E.

Biochem J. 2007 Sep 15;406(3):445-55.

35.

Ability to acquire drug resistance arises early during the tumorigenesis process.

Yagüe E, Arance A, Kubitza L, O'Hare M, Jat P, Ogilvie CM, Hart IR, Higgins CF, Raguz S.

Cancer Res. 2007 Feb 1;67(3):1130-7.

36.

Drug resistance in cancer.

Yagüe E, Raguz S.

Br J Cancer. 2005 Oct 31;93(9):973-6.

37.

Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis.

Raguz S, De Bella MT, Slade MJ, Higgins CF, Coombes RC, Yagüe E.

Int J Cancer. 2005 Dec 20;117(6):934-41.

38.

Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.

Yagüe E, Higgins CF, Raguz S.

Gene Ther. 2004 Jul;11(14):1170-4.

PMID:
15164094
39.

Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion.

Raguz S, Tamburo De Bella M, Tripuraneni G, Slade MJ, Higgins CF, Coombes RC, Yagüe E.

Clin Cancer Res. 2004 Apr 15;10(8):2776-83.

40.

Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing.

Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, Mulcahy T, Griffiths M, Edwards S, Ioannou PA, Mountain A, Crombie R.

Genomics. 2003 Sep;82(3):269-79.

PMID:
12906852
41.

P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation.

Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, Raguz S.

J Biol Chem. 2003 Mar 21;278(12):10344-52. Epub 2003 Jan 13.

42.

[Bone metastases as presentation of adrenocortical carcinoma].

Solans R, Vilardell M, Beatriz Vázquez A, Yagüe E.

Med Clin (Barc). 2001 Jan 20;116(2):76-7. Spanish. No abstract available.

PMID:
11181278
43.

Muscle-specific locus control region activity associated with the human desmin gene.

Raguz S, Hobbs C, Yagüe E, Ioannou PA, Walsh FS, Antoniou M.

Dev Biol. 1998 Sep 1;201(1):26-42.

44.
45.

Correlation of exons with functional domains and folding regions in a cellulase from Agaricus bisporus.

Yagüe E, Chow CM, Challen MP, Thurston CF.

Curr Genet. 1996 Jun;30(1):56-61.

PMID:
8662210
46.

The cel3 gene of Agaricus bisporus codes for a modular cellulase and is transcriptionally regulated by the carbon source.

Chow CM, Yagüe E, Raguz S, Wood DA, Thurston CF.

Appl Environ Microbiol. 1994 Aug;60(8):2779-85.

47.

Regulation of transcription of the cel1 gene in Agaricus bisporus.

Yagüe E, Wood DA, Thurston CF.

Mol Microbiol. 1994 Apr;12(1):41-7.

PMID:
8057839
48.

CEL1: a novel cellulose binding protein secreted by Agaricus bisporus during growth on crystalline cellulose.

Armesilla AL, Thurston CF, Yagüe E.

FEMS Microbiol Lett. 1994 Mar 1;116(3):293-9.

PMID:
8181702
49.

Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis.

González-Amaro R, García-Monzón C, García-Buey L, Moreno-Otero R, Alonso JL, Yagüe E, Pivel JP, López-Cabrera M, Fernández-Ruiz E, Sánchez-Madrid F.

J Exp Med. 1994 Mar 1;179(3):841-8.

50.

Signaling through the LFA-1 leucocyte integrin actively regulates intercellular adhesion and tumor necrosis factor-alpha production in natural killer cells.

Melero I, Balboa MA, Alonso JL, Yagüe E, Pivel JP, Sanchez-Madrid F, López-Botet M.

Eur J Immunol. 1993 Aug;23(8):1859-65.

PMID:
8344347

Supplemental Content

Support Center